Hinge Health, Inc. — Health Information Services. Scored on the same transparent 7-signal model behind the daily rankings.
★
HNGE
Hinge Health, Inc. · Health Information Services
FCF$209mC
Rev+50.6%A
D/E0.02A-
P/S10.5xC
PEG——
71.7Score
$87.49$6.8B
1Y Target$82.73Analyst consensus · 15 analysts
5Y Target$144.70Compound horizon
10Y Target$366.96Long-dated conviction
FCF$209mTTMC
FCF $209m — modest; watch for margin expansion
Rev+50.6%TTM YoYA
Revenue +50.6% — hypergrowth, top decile
D/E0.02A-
D/E 0.02 — less debt than most Healthcare peers (≈25th pctile)
P/S10.5xC
P/S 10.5x — expensive vs Healthcare peers (≈90th pctile)
PEG——
PEG not meaningful — earnings growth negative or data unavailable
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 71.7
Quality0.62
Growth1.00
Value0.59
Why this score
Short track record
Entry · Margin of safety
52-week rangeNear 52-week high
4% off the 12-month high
vs DCF fair value38% aboveest. fair value ~$63
What the price assumes: free cash flow compounding at ~23% a year for the next decade — vs the ~25% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability72% · Agross profit ÷ total assets (Novy-Marx)
Why now
Health Information Services · market cap $6.8b. 4% off the 52-week high of $91.07. Revenue growing +51% — in hypergrowth territory. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $82.73 (implying -5% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
Currently unprofitable (margin -78.9%) — path to GAAP profitability is the core thesis risk. P/S 10.5x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. ROE -457% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon
1-3 yr $82.73 (15-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $144.70 — requires the platform / technology to reach commercial scale. 10 yr $366.96 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · HNGE
Trend
-0.3 over 15 daily scores
From 72.0 (Jun 22) → 71.7 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · HNGE
$
%
%
Shares to buy
22
Position size
$1,925
3.8% of portfolio
Stop price
$65.62
25% below $87.49
$ at risk if stopped
$481.19
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Hinge Health, Inc. (HNGE): score, valuation & FAQ
Hinge Health, Inc. (HNGE) is a Health Information Services company that scores 71.7 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A) and D/E (A-). On valuation, HNGE sits about 38% above our discounted-cash-flow fair value — the current price implies roughly 23% annual free-cash-flow growth over the next decade.
Is HNGE a good stock to buy?
Bull Rankings scores HNGE 71.7 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (A) and D/E (A-). A score is a quantitative screen of Hinge Health, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does HNGE score 71.7 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). HNGE earns its highest marks on Rev (A) and D/E (A-). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is HNGE overvalued or undervalued?
Based on $87.49, HNGE sits about 38% above our discounted-cash-flow fair value — the current price implies roughly 23% annual free-cash-flow growth over the next decade. Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in HNGE?
Currently unprofitable (margin -78.9%) — path to GAAP profitability is the core thesis risk. P/S 10.5x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. ROE -457% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.